These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 31695037)

  • 1. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
    Medina-Echeverz J; Hinterberger M; Testori M; Geiger M; Giessel R; Bathke B; Kassub R; Gräbnitz F; Fiore G; Wennier ST; Chaplin P; Suter M; Hochrein H; Lauterbach H
    Nat Commun; 2019 Nov; 10(1):5041. PubMed ID: 31695037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
    Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
    J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
    Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
    J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis.
    Bella Á; Arrizabalaga L; Di Trani CA; Cirella A; Fernandez-Sendin M; Gomar C; Russo-Cabrera JS; Rodríguez I; González-Gomariz J; Alvarez M; Teijeira Á; Medina-Echeverz J; Hinterberger M; Hochrein H; Melero I; Berraondo P; Aranda F
    Oncoimmunology; 2022; 11(1):2098657. PubMed ID: 35859732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
    de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
    Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Recombinant Modified Vaccinia Ankara Virus expressing Interleukin-13 Receptor α2 Antigen for Potential Cancer Immunotherapy.
    Sato Y; Vatsan R; Joshi BH; Husain SR; Puri RK
    Curr Mol Med; 2024; 24(6):758-770. PubMed ID: 36999709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
    Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF
    Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells.
    Liu Y; Qureshi M; Xiang J
    Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD40 ligand-expressing recombinant vaccinia virus promotes the generation of CD8(+) central memory T cells.
    Trella E; Raafat N; Mengus C; Traunecker E; Governa V; Heidtmann S; Heberer M; Oertli D; Spagnoli GC; Zajac P
    Eur J Immunol; 2016 Feb; 46(2):420-31. PubMed ID: 26561341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.
    Liu J; Yu Q; Stone GW; Yue FY; Ngai N; Jones RB; Kornbluth RS; Ostrowski MA
    Vaccine; 2008 Jul; 26(32):4062-72. PubMed ID: 18562053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication.
    Hinterberger M; Endt K; Bathke B; Habjan M; Heiseke A; Schweneker M; Von Rohrscheidt J; Atay C; Chaplin P; Kalla M; Hausmann J; Schmittwolf C; Lauterbach H; Volkmann A; Hochrein H; Medina-Echeverz J
    Sci Rep; 2023 Mar; 13(1):5162. PubMed ID: 36997583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo.
    Yanagi K; Nagayama Y; Nakao K; Saeki A; Matsumoto K; Ichikawa T; Ishikawa H; Hamasaki K; Ishii N; Eguchi K
    Int J Oncol; 2003 Feb; 22(2):345-51. PubMed ID: 12527933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy.
    Shin CA; Cho HW; Shin AR; Sohn HJ; Cho HI; Kim TG
    Oncotarget; 2016 Jul; 7(29):46173-46186. PubMed ID: 27323820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced protective immunity derived from dendritic cells with phagocytosis of CD40 ligand transgene-engineered apoptotic tumor cells via increased dendritic cell maturation.
    Parameswaran S; Khalil M; Ahmed KA; Sharma RK; Xiang J
    Tumori; 2015; 101(6):637-43. PubMed ID: 25983089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.
    Moskalenko M; Pan M; Fu Y; de Moll EH; Hashimoto D; Mortha A; Leboeuf M; Jayaraman P; Bernardo S; Sikora AG; Wolchok J; Bhardwaj N; Merad M; Saenger Y
    Cancer Immunol Res; 2015 Mar; 3(3):296-304. PubMed ID: 25600438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
    Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
    Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged antitumor NK cell reactivity elicited by CXCL10-expressing dendritic cells licensed by CD40L+ CD4+ memory T cells.
    Shimizu K; Asakura M; Fujii S
    J Immunol; 2011 May; 186(10):5927-37. PubMed ID: 21460206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.